Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jose Luis Aranez

Gastroenterology Fountain Valley, CA Medical Doctor

NPI 1932466125 CMS profile 1393674

18035 Brookhurst St., Ste. 2100, Fountain Valley, CA 92708

Open in the dashboard

General payments

$2,630

107 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Luis Aranez of Fountain Valley, CA is reported in the CMS Open Payments database as having received $2,630 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $895 30
2024 General $575 22
2023 General $92 5
2022 General $507 26
2021 General $436 23
2020 General $125 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Luis Aranez
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jose Luis Aranez were reported at $895. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jose Luis Aranez Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $125 $224 $74–$624 $114
2021 $436 $352 $106–$1,054 $132
2022 $507 $448 $129–$1,270 $149
2023 $92 $533 $150–$1,390 $160
2024 $575 $605 $160–$1,606 $164
2025 $895 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,128 52 payments
  2. Boston Scientific Corporation $512 12 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $309 22 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $157 3 payments
  5. QOL Medical, LLC $139 2 payments
  6. CONMED Corporation $76 1 payment
  7. Merck Sharp & Dohme Corporation $69 4 payments
  8. Medtronic, Inc. $50 2 payments
  9. Pfizer Inc. $36 2 payments
  10. Genzyme Corporation $27 1 payment
  11. Other $126 6 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $2,630 107 payments
Products named General payments · program years 2020–2025
  1. RINVOQ $328 20 payments
  2. SKYRIZI Immunology $326 12 payments
  3. HUMIRA $312 16 payments
  4. SKYRIZI Immunology $301 15 payments
  5. XIFAXAN $276 20 payments
  6. LINZESS $190 9 payments
  7. CREON $166 7 payments
  8. ENTYVIO $157 3 payments
  9. Sucraid $139 2 payments
  10. EXALT Model D $121 1 payment
  11. Other $924 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

522

Median for Gastroenterology: 569

Drug cost

$117,435

Median for Gastroenterology: $104,976

Branded share of claims

45.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 15 $46,648
Linzess Linaclotide Brand 38 $37,208
Zenpep Lipase/Protease/Amylase Brand 11 $20,203
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 137 $7,975
Omeprazole Generic 139 $1,928
Tetracycline Hcl Generic 11 $830
Ursodiol Generic 16 $768
Famotidine Generic 43 $615
Pantoprazole Sodium Generic 43 $422
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 26 $384

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$78,346

Medicare's payments for the services billed

Medicare patients

203

Average age 74

Services billed

707

109 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 39%
Chronic kidney disease 37%
Ischemic heart disease 32%
Heart failure 25%
Atrial fibrillation 25%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $135
$135 — —
RINVOQ
  • AbbVie, Inc. $72
$72 — —
LINZESS
  • AbbVie, Inc. $43
$43 38 —
CREON
  • AbbVie, Inc. $19
$19 15 —
HUMIRA
  • AbbVie, Inc. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record